Bayer cites higher liquidity needs amid litigation procedures

• Bayer AG secured EUR 3 billion in equity capital from Apollo-managed funds to bolster liquidity needs tied to litigation procedures this year.
• The investment gives Apollo a minority, non-controlling stake in a new entity holding Bayer’s long-acting reversible contraceptives business.
• Bayer will keep a majority stake and retain full operational control.
• Bayer will keep the business within its pharmaceuticals division and continue to fully consolidate the entity.
• The deal is expected to close in Q3 2026, subject to antitrust clearance and customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2363770_en) on July 10, 2026, and is solely responsible for the information contained therein.